EUCTR2014-001363-12-NL进行中（未招募）1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial - HO133
Klinikum der Universität München, Medizinische Klinik und Poliklinik III0 个研究点目标入组 870 人开始时间: 2017年4月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed diagnosis of MCL according to WHO classification
- •2. suitable for high-dose treatment including high-dose AraC
- •3. Stage II-IV (Ann Arbor)
- •4. Age >= 18 years and <= 65 years
- •5. Previously untreated MCL
- •6. At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations.
- •7. ECOG/WHO performance status <= 2
- •8. The following laboratory values at screening (unless related to MCL):
- •- Absolute neutrophil count (ANC) >=1000 cells/uL
- •- Platelets >=100,000 cells/uL
- •- Transaminases (AST and ALT) <= 3 x upper limit of normal (ULN)
- •- Total bilirubin <= 2 x ULN unless due to known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
- •- Creatinine <=2 mg/dL or calculated creatinine clearance >= 50 mL/min
- •9. Written informed consent form according to ICH/EU GCP and national regulations
- •10. Sexually active men and women of child-bearing potential must agree to use one of the highly effective contraceptive methods (combined oral contraceptives using two hormones, contraceptive implants, injectables, intrauterine devised, sterilized partner together with one of the barrier methods (latex condoms, diaphragms, contraceptive caps) while on study; this should be maintained for 90 days after the last dose of study drug and 12 months after the last dose of rituximab.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 870
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Major surgery within 4 weeks prior to randomization.
- •2. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg phenprocoumon).
- •3. History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- •4. Requires treatment with strong CYP3A4/5 inhibitors.
- •5. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- •6. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.
- •7. Known CNS involvement of MCL.
- •8. Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation).
- •9. Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies.
- •10. Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy according to trial protocol.
- •11. Serious concomitant disease interfering with a regular therapy according to the study protocol:
- •- Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN),
- •- Pulmonary (e.g. chronic lung disease with hypoxemia),
- •- Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus),
- •- Renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinin clearance < 50 ml/min),
- •- Impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to morbus Meulengracht (Gilbert-Meulengracht-Syndrome).
- •12. Positive test results for chronic HBV infection (defined as positive HBsAg serology) (mandatory testing)
- •Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable,
- •provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody (HBSAb) after
- •vaccination are eligible.
- •13. Positive test results for hepatitis C (mandatory hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are
- •eligible only if PCR is negative for HCV RNA.
- •14. Patients with known HIV positive infection (mandatory test).
- •15. Prior organ, bone marrow or peripheral blood stem cell transplantation.
- •16. Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer.
- •17. Pregnancy or lactation.
- •18. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule.
- •19. Subjects not able to give consent.
- •20. Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial.
- •21. Participation in another clinical trial within 30 days before randomization in this study.
研究者
相似试验
进行中（未招募）
1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trialEUCTR2014-001363-12-PLKlinikum der Universität München, Medizinische Klinik und Poliklinik III870
进行中（未招募）
1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trialGeneralized mantle cell LymphomaMedDRA version: 20.0 Level: PT Classification code 10026805 Term: Mantle cell lymphoma stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10026804 Term: Mantle cell lymphoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10026803 Term: Mantle cell lymphoma stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001363-12-FIKlinikum der Universität München, Medizinische Klinik und Poliklinik III870
进行中（未招募）
1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trialPreviously untreated mantle cell LymphomaMedDRA version: 21.0Level: PTClassification code 10026805Term: Mantle cell lymphoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026804Term: Mantle cell lymphoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026803Term: Mantle cell lymphoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001363-12-DKKlinikum der Universität München, Medizinische Klinik und Poliklinik III870
进行中（未招募）
1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trialGeneralized mantle cell LymphomaMedDRA version: 21.0Level: PTClassification code 10026805Term: Mantle cell lymphoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026804Term: Mantle cell lymphoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026803Term: Mantle cell lymphoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001363-12-BEKlinikum der Universität München, Medizinische Klinik und Poliklinik III870
进行中（未招募）
1 期
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trialGeneralized mantle cell LymphomaMedDRA version: 21.0Level: PTClassification code 10026805Term: Mantle cell lymphoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026804Term: Mantle cell lymphoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026803Term: Mantle cell lymphoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001363-12-DEKlinikum der Universität München, Medizinische Klinik und Poliklinik III870